What research findings exist for Semaglutide in weight management and weight loss maintenance?
44 weeks of weight loss reached the preset equivalence standard compared with reference semaglutide. Additionally, a study report showed: the semaglutide group had an average weight loss of 15.2%, placebo 2.6%, supporting continued weight loss over two years.[1] ↗ [2] ↗
Currently, 3 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.
Comparison of study design and results
Results from different populations, species, materials, or follow-up times cannot be directly combined. The table below is a comparative summary of published data, not new experimental data.
| Literature | Study subjects and design | Observation and discovery | Scope of Explanation |
|---|---|---|---|
| 2026 · PMID 42839752 | Human Randomization Phase III; Obese adults in China | 44 weeks of weight loss reached the preset equivalence standard compared with reference semaglutide. | Studies HD1916 and Wegovy, and cannot conclude that Ventro formulation is equivalent on this basis. |
| 2022 · PMID 36216945 | STEP5; 304 adults with obesity or overweight without diabetes; 104-week randomized controlled trial | The Semaglutide group showed an average weight loss of 15.2%, compared to 2.6% with placebo, supporting sustained weight loss over two years. | Both groups received behavioral interventions; mainly white women; gastrointestinal adverse events were more common. The formulations in the papers are different from research commodities. |
| 2021 · PMID 33567185 | 1,961 overweight or obese adults without diabetes; STEP1 randomized trial, 68 weeks | In the semaglutide group, the average body weight decreased by 14.9%, and in the placebo group by 2.4%, directly supporting weight management research. | Both groups had lifestyle interventions; basic research in 2021, gastrointestinal reactions were common; study formulations do not represent catalog products. |
References
What does the study’s weight loss equivalence comparison of preparations indicate?
44 weeks of weight loss reached the preset equivalence standard compared with reference semaglutide.[1] ↗
Human Randomization Phase III; Obese adults in China
Studies HD1916 and Wegovy, and cannot conclude that Ventro formulation is equivalent on this basis.
View the Article Title and Full Citation＋
Efficacy and Safety of Chemically Synthesized Semaglutide Injection (HD1916) for the Treatment of Obesity: A Multicenter, Randomized, Phase III Trial.
Diabetes, obesity & metabolism · Volume and Issue Year 2026
First published 2026-10-07 · PMID 42839752
DOI 10.1111/dom.71354
What was observed during the two-year follow-up?
The Semaglutide group showed an average weight loss of 15.2%, compared to 2.6% with placebo, supporting sustained weight loss over two years.[2] ↗
STEP5; 304 adults with obesity or overweight without diabetes; 104-week randomized controlled trial
Both groups received behavioral interventions; mainly white women; gastrointestinal adverse events were more common. The formulations in the papers are different from research commodities.
View the Article Title and Full Citation＋
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
Nature medicine · Volume/Issue Year 2022
First published 2022-10-01 · PMID 36216945
DOI 10.1038/s41591-022-02026-4
What were the findings of the 68-week weight management study?
In the semaglutide group, the average body weight decreased by 14.9%, and in the placebo group by 2.4%, directly supporting weight management research.[3] ↗
1,961 overweight or obese adults without diabetes; STEP1 randomized trial, 68 weeks
Both groups had lifestyle interventions; basic research in 2021, gastrointestinal reactions were common; study formulations do not represent catalog products.
View the Article Title and Full Citation＋
Once-Weekly Semaglutide in Adults with Overweight or Obesity.
The New England Journal of Medicine · Volume, Issue, Year 2021
First published 2021-02-10 · PMID 33567185
DOI 10.1056/NEJMoa2032183
Common issues and corresponding evidence
What research findings exist for Semaglutide in weight management and weight loss maintenance?＋
44 weeks of weight loss reached the preset equivalence standard compared with reference semaglutide. Additionally, a study report showed: the semaglutide group had an average weight loss of 15.2%, placebo 2.6%, supporting continued weight loss over two years.[1] ↗ [2] ↗
How long was the long-term weight management study?＋
STEP5 extended the follow-up to 104 weeks. The semaglutide group had an average weight loss of 15.2%, compared to 2.6% in the placebo group. These are two-year results and should not be directly ranked against trials of other durations.[2] ↗
Semaglutide—these conclusions apply to which study populations?＋
Randomized phase III human study in Chinese adults with obesity; STEP5 included 304 adults with obesity or overweight without diabetes in a 104-week randomized controlled trial; STEP1 included 1961 adults with overweight or obesity without diabetes in a 68-week randomized trial. The formulations studied were HD1916 and Wegovy; these findings do not establish equivalence of Ventro's formulation.[1] ↗ [2] ↗ [3] ↗
Semaglutide
Return to catalog specifications and batch file verification entry.
